SCHEMBL874677

SCHEMBL874677

O=C(Nc1ccc(S(=O)(=O)C(CCn2nnc3ccccc3c2=O)C(=O)O)cc1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 1/20 0.45
KMT2A Q03164 5/20 0.44
MEN1 O00255 2/20 0.44
ALDH1A1 P00352 3/20 0.44
HSD17B10 Q99714 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KDM4E B2RXH2 1/20 0.44
HDAC1 Q13547 1/20 0.42
GAA P10253 2/20 0.41
USP2 O75604 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
DGAT1 O75907 1/20 0.41
MGAM O43451 1/20 0.41
AMY1A P0DUB6 1/20 0.41
SI P14410 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL878191 0.91 ALDH1A1 (0.49) KMT2AMEN1ALDH1A1HSD17B10L3MBTL1
SCHEMBL874492 0.90 KMT2A (0.49) PRMT1KMT2AMEN1ALDH1A1HSD17B10
SCHEMBL878389 0.90 CTNNB1 (0.45) PRMT1HTTDGAT1PTGDR2
SCHEMBL874410 0.88 HTT (0.54) KMT2AMEN1ALDH1A1HSD17B10L3MBTL1
SCHEMBL875318 0.88 KMT2A (0.46) KMT2AMEN1ALDH1A1HSD17B10L3MBTL1
SCHEMBL875017 0.87 HTT (0.47) KMT2AMEN1ALDH1A1HSD17B10L3MBTL1
SCHEMBL875418 0.87 KMT2A (0.45) KMT2AMEN1ALDH1A1HSD17B10L3MBTL1
SCHEMBL877579 0.85 KMT2A (0.50) KMT2AMEN1ALDH1A1HSD17B10L3MBTL1
SCHEMBL877210 0.85 KMT2A (0.41) KMT2AMEN1ALDH1A1HSD17B10L3MBTL1
SCHEMBL875118 0.85 TSHR (0.52) KMT2AMEN1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US claimed
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US disclosed
EP-2619185-A1 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2013-07-31 EP disclosed
WO-2012038942-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP12, MMP10 PRMT1 2394/4885KMT2A 3501/4885MEN1 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.